Phase I Clinical Study of VIC-1911 Combined With Osimertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGRF- Mutation
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Osimertinib (Primary) ; TAS 119 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Jiesi Yingda Pharmaceutical Technology
Most Recent Events
- 04 Jun 2024 Results (n=24, As of 18 December 2023 ) evaluating the safety and efficacy of VIC-1911 plus osimertinib in patients with TKI-resistant, EGFRmt NSCLC were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 12 Jun 2023 Status changed from not yet recruiting to recruiting.
- 11 Aug 2022 New trial record